Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France
Elise Maurat
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France
Jean-Marc Sac-Epée
Univ-Lorraine, Institut Elie Cartan de Lorraine, Vandoeuvre-lès-Nancy, France
Pauline Henrot
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France; Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Center for Infection Research (HZI), Würzburg, Germany
Maeva Zysman
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France; Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Center for Infection Research (HZI), Würzburg, Germany
Pauline Esteves
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France
Thomas Trian
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France
Jean-William Dupuy
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France
Alexander Leipold
Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Center for Infection Research (HZI), Würzburg, Germany
Antoine-Emmanuel Saliba
Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Center for Infection Research (HZI), Würzburg, Germany
Hugues Begueret
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France; CHU de Bordeaux, Service d’exploration fonctionnelle respiratoire, Pessac, France
Pierre-Olivier Girodet
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France; CHU de Bordeaux, Service d’exploration fonctionnelle respiratoire, Pessac, France
Matthieu Thumerel
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France; CHU de Bordeaux, Service d’exploration fonctionnelle respiratoire, Pessac, France
Romain Hustache-Castaing
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France; CHU de Bordeaux, Service d’exploration fonctionnelle respiratoire, Pessac, France
Roger Marthan
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France; CHU de Bordeaux, Service d’exploration fonctionnelle respiratoire, Pessac, France
Florian Levet
Univ. Bordeaux, CNRS, INSERM, Bordeaux Imaging Center, Bordeaux, France; Univ. Bordeaux, CNRS, Interdisciplinary Institute for Neuroscience, Bordeaux, France
Pierre Vallois
Univ-Lorraine, Institut Elie Cartan de Lorraine, Vandoeuvre-lès-Nancy, France
Cécile Contin-Bordes
CNRS, UMR5164 ImmunoConcEpT, Université de Bordeaux, Bordeaux, France; CHU de Bordeaux, Laboratoire d’Immunologie et Immunogénétique, Bordeaux, France
Patrick Berger
Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC1401, Proteomics Facility, Pessac, France; INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Pessac, France; CHU de Bordeaux, Service d’exploration fonctionnelle respiratoire, Pessac, France
Bronchi of chronic obstructive pulmonary disease (COPD) are the site of extensive cell infiltration, allowing persistent contact between resident cells and immune cells. Tissue fibrocytes interaction with CD8+ T cells and its consequences were investigated using a combination of in situ, in vitro experiments and mathematical modeling. We show that fibrocytes and CD8+ T cells are found in the vicinity of distal airways and that potential interactions are more frequent in tissues from COPD patients compared to those of control subjects. Increased proximity and clusterization between CD8+ T cells and fibrocytes are associated with altered lung function. Tissular CD8+ T cells from COPD patients promote fibrocyte chemotaxis via the CXCL8-CXCR1/2 axis. Live imaging shows that CD8+ T cells establish short-term interactions with fibrocytes, that trigger CD8+ T cell proliferation in a CD54- and CD86-dependent manner, pro-inflammatory cytokines production, CD8+ T cell cytotoxic activity against bronchial epithelial cells and fibrocyte immunomodulatory properties. We defined a computational model describing these intercellular interactions and calibrated the parameters based on our experimental measurements. We show the model’s ability to reproduce histological ex vivo characteristics, and observe an important contribution of fibrocyte-mediated CD8+ T cell proliferation in COPD development. Using the model to test therapeutic scenarios, we predict a recovery time of several years, and the failure of targeting chemotaxis or interacting processes. Altogether, our study reveals that local interactions between fibrocytes and CD8+ T cells could jeopardize the balance between protective immunity and chronic inflammation in the bronchi of COPD patients.